Valuation
INMDInmode Ltd
StockNasdaqイスラエルHealth careEU retail: available
9/10
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | INMD | Sector median | vs median |
|---|---|---|---|
| P/E | 9.6 | 15.6 · n=8 | 38% below |
| P/B | 1.3 | 2.3 · n=14 | 43% below |
| P/S | 2.4 | 3.5 · n=11 | 30% below |
| EV/EBIT | 6.1 | 16.9 · n=7 | 64% below |
| Free-cash-flow yield | 9.3% | 5.0% · n=12 | 88% above |
| Dividend yield | 0.00% | 1.67% · n=58 | 100% below |
| Return on equity | 13.5% | 2.5% · n=14 | 447% above |
| Return on invested capital | 15.6% | 4.6% · n=11 | 239% above |
| Gross margin | 78.5% | 66.3% · n=8 | 18% above |
| Net debt / EBITDA | −4.49 | — | — |
Value factor: 98 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| Instrument | P/E | P/B | EV/EBIT | Free-cash-flow yield | Dividend yield | Smart Score |
|---|---|---|---|---|---|---|
| NVSNovartis AG | 20.0 | 6.1 | 16.9 | 6.3% | 3.2% | 10/10 |
| SNYSanofi | 11.1 | 1.2 | 15.3 | 8.3% | 6.1% | 7/10 |
| ALCAlcon | 31.8 | 1.4 | 25.2 | 5.6% | 0.6% | 5/10 |
| BNTXBioNTech SE | — | 1.0 | — | 1.4% | 0.0% | —/10 |
| STESTERIS | 26.3 | 2.9 | 19.8 | 4.4% | 0.9% | 7/10 |
| ICLRICON plc | 307.9 | 1.4 | 56.6 | 6.8% | 0.0% | 3/10 |
| CRSPCRISPR Therapeutics AG | — | 2.8 | — | −7.6% | 0.0% | 1/10 |
| ABCLAbCellera Biologics | — | 4.2 | — | −3.2% | 0.0% | 1/10 |
| ZLABZai Lab Ltd | — | 4.2 | — | −5.5% | 0.0% | 1/10 |
| AUPHAurinia Pharmaceuticals | 7.0 | 3.6 | — | — | 0.0% | —/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 12月 2025 · filed 10 2月 2026
ここで契約を解約する · EU消費者向け：購入から14日以内の返品が可能。